Announcement
28 Jan 2021
In January 2021, the Norwegian authorities introduced an export notification on rivaroxaban; certain immunoglobulins (IOVIG 100MG/ML, 300 ml hgl; hizentra 200 mg/ml, 10x10 ml hgl; 200 mg/ml, 20 ml hgl og 50 ml hgl 100 mg/ml, 200 ml hgl); salmeterol; formoterol & budesonide; palivizumab; pertuzumab; formoterol & beclomethasone; formoterol, glycopyrronium bromide & beclomethasone; and certain cyclesonide (160 mcg/dose) following the outbreak of COVID-19.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
28 Jan 2021
Revocation date:
01 Jul 2023
Updated: 28 Jan 2021
Export licensing requirement
On 28 January 2021, the Norwegian Medicines Agency introduced an export notification on rivaroxaban; certain immunoglobulins (IOVIG 100MG/ML, 300 ml hgl; hizentra 200 mg/ml, 10x10 ml hgl; 200 mg/ml...
Sign in to see more
Related State Acts
03 Mar 2021
Norway: Introduction and subsequent removal of export ban on all immunoglobulins
07 Jan 2021
Norway: Introduction of export ban on certain rivaroxaban and salmeterol
03 Dec 2020
Norway: Introduction of export ban on certain rivaroxaban, certain immunoglobulins and formoterol & budesonide (COVID-19)
09 Oct 2020
Norway: Introduction of export ban on formoterol and beclomethasone, formoterol, glycopyrronium and bromide as well as ciclesonide following the outbreak of COVID-19
05 Aug 2020
Norway: Introduction of export ban on pertuzumab (COVID-19)
29 Jul 2020
Norway: Introduction of export ban on rivaroxaban, apixaban, immunoglobulins and palivizumab (COVID-19)
Threads
See all
This state act is not part of any Thread yet.